[{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Final Approval of its ANDA for Pomalidomide Capsules (Generic for Pomalyst\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Pomalidomide","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma Limited","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma Limited"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Final Approval of its ANDA for Everolimus Tablets (Generic for Afinitor\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Everolimus","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Natco pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Natco pharma"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Aggrega Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Breckenridge Signs Multi-Product Agreement With Aggrega Pharma LLC","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Succinylcholine Chloride","moa":"Ach receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Aggrega Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Aggrega Pharma"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Everolimus 10mg (Afinitor) Launched","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Everolimus","moa":"kinase","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Axplora","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teriflunomide \u2013 API and Licensing Agreements for Tablets Available","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"DHODH","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Breckenridge","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Breckenridge"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"MSN Laboratories","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Pharmaceutical, Inc. Announces Launch of Lacosamide Tablets, USP (generic version of Vimpat\u00ae) Manufactured by MSN Laboratories Private Limited","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Breckenridge Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Breckenridge Pharmaceutical"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Aggrega Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Pharmaceutical, Inc. Announces Launch of Penicillamine Capsules, USP (generic for Cuprimine\u00ae)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Penicillamine","moa":"Copper","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Breckenridge Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Breckenridge Pharmaceutical"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Approval of its ANDA for Miglustat Capsules (generic for Zavesca\u00ae)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Miglustat","moa":"Glucosylceramide synthase","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Tentative Approval of its ANDA for Dabigatran Etexilate Capsules (generic for Pradaxa\u00ae)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Dabigatran Etexilate Mesylate","moa":"Thrombin","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Natco Pharma's Partner Breckenridge Gets FDA Nod for Prostate Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"Microtubule","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Natco","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Natco"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Natco Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Approval of its ANDA for Cabazitaxel Intravenous Solution (Generic for Jevtana Kit\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Cabazitaxel","moa":"Microtubule","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"Cytotoxic Drug","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Natco Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Natco Pharma"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Final Approval of its ANDA for Everolimus Tablets (generic for Zortress\u00ae)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Everolimus","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Final Approval of its ANDA for Asenapine Sublingual Tablets, 5 mg Strength (generic for Saphris\u00ae)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Asenapine Maleate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Final Approval of its ANDA for Asenapine Sublingual Tablets, 2.5 and 10mg Strengths (generic for Saphris\u00ae)","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Asenapine Maleate","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Pharmaceutical, Inc. Announces Launch of Penicillamine Capsules, USP (generic for Cuprimine\u00ae)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Penicillamine","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Pharmaceutical, Inc. Announces Launch of Norepinephrine Bitartrate Injection, USP (generic for Levophed\u00ae)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Norepinephrine Bitartrate","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Hormone","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ANDA Approval for Teriflunomide Tablets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apixaban Tablets (generic for Eliquis\u00ae) Approved","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Apixaban","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Announces Approval of its ANDA for Carfilzomib Intravenous Powder (generic for Kyprolis\u00ae)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Carfilzomib","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Breckenridge Pharmaceutical, Inc. Announces Launch of Zolpidem Tartrate Extended-Release Tablets, USP (generic for Ambien\u00ae CR)","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Zolpidem Tartrate","moa":"","url1":"","url2":"","graph1":"Sleep","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Sleep","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Breckenridge Pharmaceutical
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
